Pacira Pharmaceuticals Inc. (PCRX)
  • Россия
  • Украина

Pacira Pharmaceuticals Inc. (PCRX)

Contact Details

5 Sylvan Way Ste 300, Parsippany, New Jersey, USA 07054-3813
(973) 254-3560
5 Sylvan Way Ste 300, Parsippany, New Jersey, USA 07054-3813

General Information

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Pacira Pharmaceuticals, Inc. is based in New Jersey.

Contact Information

Phone(973) 254-3560
Website 1
Thomson Reuters PermID4297853578


NamePositionTotal Annual CompensationYearPercent Change in Compensation
David M. StackPresident and CEO$7,410,2382014706.4%
James S. (Jim) ScibettaCFO and Senior VP$3,515,3182014649.5%
Dr. Taunia Markvicka, Pharm.D.Other Executive Officer and Senior VP$3,483,8892014658.1%
Gary Patou,M.D.Chief Medical Officer$1,885,0432014412.8%
Ms. Kristen Marie WilliamsChief Administrative Officer, General Counsel and Secretary$2,150,0442014

Corporate Data


  • Pharmaceutical Preparation Manufacturing

SIC Industries

  • Pharmaceutical Preparations

Company Size

Sales Volume$249 million


Ticker SymbolPCRX
ExchangeNASDAQ Global Select Market
Year Founded2007


Previous Close60.28
Bid60.22 x 200
Ask60.45 x 200
Day`s Range59.81 - 61.73
52-Week Range36.62 - 92.39
Average Volume (1M)651,472
Forward P/E6,058x
Trailing P/E432.71x
Market Cap.$2,244.67 Million


Period EndingDec. 31, 2015Sep. 30, 2015Jun. 30, 2015Mar. 31, 2015
Total Revenue69,32062,21359,14858,316
Cost of Revenue19,42715,90118,92917,580
Gross Profit49,89346,31240,21940,736
Research Development13,1535,8933,6495,967
Selling General and Administrative37,55335,31034,75231,428
Depreciation and Amortization----
Other Operating Expenses----
Total Operating Expenses70,13357,10457,33054,975
Other Income/Expenses Net----
Earnings Before Interest and Taxes(813)5,1091,8183,341
Interest Expense1,8841,9051,9401,996
Income Before Tax(2,606)3,367471,312
Income Tax Expense(108)2813952
Minority Interest----
Net Income from Continuing Ops(2,498)3,08681,260
Discontinued Operations----
Extraordinary Items----
Effect of Accounting Changes----
Other Items----
Net Income(2,498)3,08681,260
Preferred Stock and Other Adjustments----
Net Income Applicable to Common Shares(2,498)3,08681,260